Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital

Cover Page

Cite item

Full Text

Abstract

Study of molecular and genetic features of diffuse large B-cell lymphoma (DLBCL) suggests differential approach to treatment of this aggressive B-cell disorder characterized by short remission after each subsequent therapy line. Therefore, more effective regimens should be used at earlier stages. Identification of biological markers and their integration into prognostic scales can help to personalize therapy, especially in patients with high risk of quick progression and increase survival.

Our own experience of using immunoconjugate polatuzumab vedotin in therapy of patients with DLBCL. The use of Pola-BR combination in a patient with refractory non-GCB DLBCL allowed to achieve full remission alongside satisfactory tolerability and absence of significant adverse events. An evaluation of the Pola-R-CHP regimen in treatment of a patient with newly diagnosed generalized GCB DLBCL is presented.

About the authors

Yu. E. Ryabukhina

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Author for correspondence.
Email: gemonk.yur@mail.ru
ORCID iD: 0000-0001-8443-8816

Yulia E. Ryabukhina 

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

P. A. Zeynalova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-1564-424X

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081,

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

O. L. Timofeeva

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-6229-7300

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

F. M. Abbasbeyli

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-2359-0547

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

A. G. Zhukov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0001-5353-8857

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

T. T. Valiev

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0002-1469-2365

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

References

  1. Ruppert A.S., Dixon J.G., Salles G. et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 2020;135(23):2041–8. doi: 10.1182/blood.2019002729
  2. Sehn L.H., Salles G. Diffuse large B-cell lymphoma. N Engl J Med 2021;384(9):842–58. doi: 10.1056/NEJMra2027612
  3. WHO classification of tumours oh haematopoetic and lymphoid tissues. Ed. by S.H. Swerdlov, E. Campo, N.L. Harris et al. Revised 4th edn. WHO Press, 2017.
  4. Scott D.W., King R.L., Staiger A.M. et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 2018;131(18):2060–4. doi: 10.1182/blood-2017-12-820605
  5. Rosenwald A., Bens S., Advani R. et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2019;37(35):3359–68. doi: 10.1200/JCO.19.00743
  6. Hu S., Xu-Monette Z.Y., Tzankov A. et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121(20):4021–31. doi: 10.1182/blood-2012-10-460063
  7. Savage K.J., Slack G.W., Mottok A. et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 2016;127(18):2182–8. doi: 10.1182/blood-2015-10-676700
  8. Devi K., Shaikh M.U., Ali N.B. et al. Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: a single-center experience. Leuk Res Rep 2021;16:100284. doi: 10.1016/j.lrr.2021.100284
  9. Ma Q., Chang Y., Li L. et al. Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. Cancer Manag Res 2019;11:1363–72. doi: 10.2147/CMAR.S192143
  10. Chen Y., Cai Q., Chang Yu. et al. High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma. Front Immunol 2022;13:1047115. doi: 10.3389/fimmu.2022.1047115
  11. Nowakowski G.S., Chiappella A., Gascoyne R.D. et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 2021;39(12):1317–28. doi: 10.1200/JCO.20.01366
  12. Davies A., Cummin T.E., Barrans S. et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol 2019;20(5):649–62. doi: 10.1016/S1470-2045(18)30935-5
  13. Younes A., Sehn L.H., Johnson P. et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019;37(15):1285–95. doi: 10.1200/JCO.18.02403
  14. Crump M., Neelapu S., Farooq U. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130(16):1800–8. doi: 10.1182/blood-2017-03-769620
  15. Sawalha Y., Maddocks K. Profile of polatuzumab vedotin in the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: a brief report on the emerging clinical data. Onco Targets Ther 2020;13:5123–33. doi: 10.2147/OTT.S219449
  16. Instructions for the medical use of the drug Polatuzumab vedotin, LP-006599.
  17. Polson A.G., Yu S.F., Elkins K. et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 2017;110(2):616–23. doi: 10.1182/blood-2007-01-066704
  18. Papageorgiou S.G., Thomopoulos T.P., Liaskas A., Vassilakopoulos T.P. Antibodies in the treatment of diffuse large B-cell lymphoma: moving beyond rituximab. Cancers (Basel) 2022;14(8):1917. doi: 10.3390/cancers14081917
  19. Assi R., Masri N., Dalle I.A. et al. Polatuzumab vedotin: current role and future applications in the treatment of patients with diffuse large B-cell lymphoma. Clin Hematol Int 2021;3(1):21–6. doi: 10.2991/chi.k.210305.001
  20. Palanca-Wessels M.C., Czuczman M., Salles G. et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 2015;16(6):704–15. doi: 10.1016/S1470-2045(15)70128-2
  21. Morschhauser F., Flinn I.W., Advani R. et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 2019;6(5):e254–e65. doi: 10.1016/S2352-3026(19)30026-2
  22. European Medicines Agency. POLIVY summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/polivy-epar-product-information_en.pdf (accessed 11.09.2020).
  23. Sehn L.H., Herrera A.F., Flowers C.R. et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155–165. doi: 10.1200/JCO.19.00172
  24. Sehn L., Hertzberg M., Opat S. et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv 2022;6(2):533–43. doi: 10.1182/bloodadvances.2021005794
  25. Tilly H., Morschhauser F., Sehn L.H. et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351–63. doi: 10.1056/NEJMoa2115304
  26. Zhang W.R., Liu X., Zhong Q.Z. et al. Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival. Cancer Med 2024;13(1):e6899. doi: 10.1002/cam4.6899
  27. Herrera A.F., McCord R., Komes P. et al. Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): results from the POLARIX study. Blood 2022;140(Suppl 1):1297–300. doi: 10.1182/blood-2022-157559
  28. Draft clinical recommendations “Aggressive non-follicular lymphomas - diffuse large-cell B-cell lymphoma, primary mediastinal B-cell lymphoma, Burkitt lymphoma”. Available at: https://rusoncohem.ru/klinrec/agressivnye-nefollikulyarnyelimfomy-proekt-2021-2022/ (acсess 15.12.2022).
  29. Sarkozy C., Sehn L.H. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol 2018;31(3):209–16. doi: 10.1016/j.beha.2018.07.014
  30. Fabbri N., Mussetti A., Sureda A. Second-line treatment of diffuse large B-cell lymphoma: evolution of options. Semin Hematol 2023;60(5):305–12. doi: 10.1053/j.seminhematol.2023.12.001
  31. Shi X., Liu X., Li X. et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and International Prognostic Index: a multicenter retrospective study. Front Oncol 2021;11:754964. doi: 10.3389/fonc.2021.754964
  32. Pasqualucci L., Trifonov V., Fabbri G. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43(9):830–7. doi: 10.1038/ng.892
  33. Hilton L.K., Scott D.W., Morin R.D. Biological heterogeneity in diffuse large B-cell lymphoma. Semin Hematol 2023;60(5):267–76. doi: 10.1053/j.seminhematol.2023.11.006
  34. Schmitz R., Wright G.W., Huang D.W. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018;378(15):1396–407. doi: 10.1056/NEJMoa1801445
  35. Chapuy B., Stewart C., Dunford A.J. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018;24(5):679–90. doi: 10.1038/s41591-018-0016-8
  36. Abramson J.S., Solomon S.R., Arnason J.E. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood 2023;141(14):1675–84. doi: 10.1182/blood.2022018730
  37. Locke F.L., Miklos D.B., Jacobson C.A. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640–54. doi: 10.1056/NEJMoa2116133

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.